TABLE 3.

Patient Characteristics, N = 60

Characteristic	No. of Patients
Age: Median (range). y	41 (16–65)
Sex
Men	36
Women	24
Primary refractory tumora	28%
Poor-risk or refractory relapsea	62%
Primary refractory tumora	28%
Poor-risk or refractory relapsea	62%
Median no. of prior chemotherapy lines (range)	3 (2–7)
Prior radiotherapy	17%
Disease status at HDC
CR	68%
PR	25%
Unresponsive	7%
PET-positive at HDC	32%
Diagnoses
DLBCL	26
Double hit (MYC/BCL2)	4
Triple hit (MYC/BCL2/BCL6)	2
Double expression of MYC/BCL2	4
Cell of origin
Germinal center	10
Activated B cell	11
Primary mediastinal	3
Not determined	2
Primary refractory (induction PR/induction failure)	5
Relapsed	21
Secondary IPI score
0–1	9
2	6
>3	6
First relapse	14
Length of CR1
<12 mo	8
≥12 mo	6
Second relapse or later	7
Primary CNS lymphoma	1
Transformed lymphoma	2
Hodgkin lymphoma	21
Primary refractory	12
Poor-risk relapse	9
First relapse	5
Second relapse or later	4
Extranodal disease at relapse/PD	11
Bulky tumor at relapse/PD	14
B-symptoms at relapse/PD	1
T-NHL	8
Histology
PTCL NOS	3
ALCL	2
NK-T	2
AITL	1
Primary refractory	0
Primary relapsed	8
Follicular lymphoma	3
Mantle cell lymphoma	2

Abbreviations: ALCL, anaplastic large-cell lymphoma; AITL angioimmunoblastic T-cell lymphoma; BCL2, B-cell lymphoma 2; BCL6, B-cell lymphoma 6 protein; CNS, central nervous system; CR, complete response; CR1, first complete response; DLBCL, diffuse large B-cell lymphoma; HDC, high-dose chemotherapy; IPI, International Prognostic Index; NK-T, natural killer-T cell; MYC, v-myc avian myelocytomatosis viral oncogene homolog; NOS, not otherwise specified; PD, progressive disease; PET, positron emission tomography; PR, partial response; PTCL, peripheral T-cell lymphoma; T-NHL, T-cell non-Hodgkin lymphoma.

^aFor definitions of “primary refractory tumor,” “poor-risk relapse,” and “refractory relapse,” see the text (Materials and Methods, Patient Population).